Form 4: Zoetis EVP Sarbaugh Receives Equity Grants

Zoetis Inc. Executive Vice President Keith Sarbaugh was granted 2,674 Restricted Stock Units and 10,581 Stock Options on February 18, 2026, as part of the company's equity incentive plan.

Summary

• Executive Vice President Keith Sarbaugh of Zoetis Inc. (ZTS) was granted 2,674 Restricted Stock Units (RSUs) and 10,581 Stock Options on February 18, 2026.
• The RSUs represent a contingent right to receive one share of Zoetis Inc. common stock each, including dividend equivalent units.
• The stock options grant the right to buy Zoetis Inc. common stock at an exercise price of $129.13 per share.
• According to the filing's explanation, both the new RSUs and stock options are scheduled to vest in one-third increments on the first, second, and third anniversaries of the grant date, February 18, 2026. (Note: This phrasing in the filing is ambiguous and appears contradictory if the grant date is indeed February 18, 2026, as it would imply immediate vesting or future vesting starting February 18, 2027, not the third anniversary).
• The stock options will expire on the tenth anniversary of the grant date.
• These grants were made under the Zoetis Inc. Amended and Restated 2013 Equity and Incentive Plan.
• Sarbaugh also beneficially owns previously granted RSUs (1,159.7099 vesting Feb 19, 2025; 120 vesting Feb 6, 2024; 1,528.0167 vesting March 31, 2023) and Stock Options (4,453 with exercise price $156.64 vesting Feb 19, 2025; 1,348 with exercise price $196.14 vesting Feb 6, 2024; 3,142 with exercise price $166.44 vesting March 31, 2023).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it reinforces executive alignment with shareholder interests through long-term equity incentives, a standard and healthy corporate governance practice. The ambiguity in dates is a minor concern but does not detract from the overall positive intent.

Positives

• The grant of equity awards aligns the interests of Executive Vice President Keith Sarbaugh with those of shareholders, incentivizing long-term performance and stock price appreciation.
• The vesting schedule, typically over three years, encourages retention of key executives.

Negatives

• The issuance of new equity awards, particularly stock options, can lead to potential future dilution for existing shareholders if the options are exercised.
• The ambiguity in the filing regarding the exact grant date and vesting schedule for the new awards creates a lack of clarity.

Risks

• The value of the granted Restricted Stock Units and Stock Options is tied to the future performance of Zoetis Inc.'s common stock, meaning the awards may not realize their full potential value if the stock price declines.
• The long-term nature of the vesting schedule means the executive's compensation is subject to market fluctuations over several years.

Future Outlook

The filing indicates a continued commitment to long-term incentive compensation for executive leadership, with new equity awards vesting over a multi-year period, aligning future executive performance with shareholder value creation.

Industry Context

StockSavvy.ai notes that the grant of Restricted Stock Units and Stock Options is a standard practice in executive compensation across the pharmaceutical and animal health industries. This approach aims to align executive incentives with long-term company performance and shareholder returns, a common strategy for retaining top talent in competitive sectors.

Comparison to Industry Standards

• The use of both Restricted Stock Units (RSUs) and Stock Options is a common hybrid approach in executive compensation packages within the S&P 500, including peers like Elanco Animal Health (ELAN) and IDEXX Laboratories (IDXX), balancing direct equity ownership with performance-based incentives.
• A multi-year vesting schedule for equity awards is typical for executive grants in the animal health sector, comparable to practices at companies such as Merck Animal Health (part of MRK) and Ceva Santé Animale, promoting long-term commitment and discouraging short-term decision-making.
• The specific number of units granted to an Executive Vice President at Zoetis appears to be within the expected range for a company of its market capitalization and industry, reflecting a competitive compensation structure designed to attract and retain senior leadership.

Stakeholder Impact

• Shareholders: Potential for increased alignment of executive interests with shareholder value creation. Minor potential for future dilution upon option exercise.
• Employees: May signal stability in executive leadership and a consistent approach to executive compensation.
• Management: Provides long-term incentives and compensation tied to company performance and stock price.

Next Steps

• Assuming the grant date is February 18, 2026, one-third of the newly granted RSUs and Stock Options are expected to vest on February 18, 2027.
• Subsequent one-third vesting events for the new awards would then occur on February 18, 2028, and February 18, 2029.
• The newly granted stock options will expire on February 18, 2036.

Key Dates

Recommendation

This Form 4 filing reports routine executive equity grants, which are a standard component of compensation and align management incentives with shareholder interests. While positive for governance, it does not present new information significant enough to alter the fundamental investment thesis for Zoetis Inc. A 'hold' recommendation is appropriate as this filing does not introduce factors warranting a change in existing positions.

Keywords

Zoetis Inc., ZTS, SEC Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Equity Grant, Executive Compensation, Keith Sarbaugh, Corporate Governance